Insulet Corporation (NASDAQ:PODD) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Insulet Corporation (NASDAQ:PODD) have earned a consensus recommendation of “Moderate Buy” from the twenty-eight research firms that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and twenty-two have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $235.25.

PODD has been the subject of a number of analyst reports. William Blair started coverage on shares of Insulet in a research report on Wednesday, May 20th. They issued an “outperform” rating for the company. JPMorgan Chase & Co. reduced their price target on shares of Insulet from $340.00 to $275.00 and set an “overweight” rating for the company in a research report on Thursday, May 7th. Rothschild & Co Redburn reaffirmed a “neutral” rating and issued a $220.00 price target (down from $380.00) on shares of Insulet in a research note on Friday, April 24th. Robert W. Baird cut their price objective on Insulet from $360.00 to $248.00 in a research note on Thursday, May 7th. Finally, Raymond James Financial set a $216.00 target price on Insulet in a report on Monday, June 8th.

Insiders Place Their Bets

In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of the stock in a transaction on Wednesday, June 3rd. The shares were bought at an average price of $143.51 per share, with a total value of $400,392.90. Following the purchase, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. This trade represents a 44.63% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.36% of the company’s stock.

Hedge Funds Weigh In On Insulet

Several hedge funds and other institutional investors have recently modified their holdings of PODD. Norges Bank purchased a new stake in Insulet during the 4th quarter valued at about $300,794,000. Arrowstreet Capital Limited Partnership lifted its stake in Insulet by 462.7% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock worth $258,088,000 after purchasing an additional 1,011,369 shares in the last quarter. RTW Investments LP purchased a new position in Insulet in the 4th quarter worth approximately $92,264,000. AQR Capital Management LLC boosted its holdings in shares of Insulet by 161.6% during the 4th quarter. AQR Capital Management LLC now owns 459,115 shares of the medical instruments supplier’s stock worth $130,499,000 after purchasing an additional 283,643 shares during the last quarter. Finally, SG Americas Securities LLC grew its position in shares of Insulet by 712.1% in the first quarter. SG Americas Securities LLC now owns 318,848 shares of the medical instruments supplier’s stock valued at $66,907,000 after purchasing an additional 279,587 shares in the last quarter.

Key Stories Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: No clearly positive company-specific catalysts were identified in the latest news flow.
• Neutral Sentiment: Multiple law firms, including Pomerantz, Schall, Robbins, Rosen, Faruqi, Gross, Bronstein, Levi & Korsinsky, and BFA Law, issued class-action filings or investor reminders related to PODD shares purchased between February 2025 and May 2026, keeping the issue in the spotlight. Pomerantz Law Firm article
• Neutral Sentiment: The litigation references an August 31, 2026 lead-plaintiff deadline, suggesting the legal process is still in an early procedural stage rather than reflecting a final outcome. SueWallSt deadline reminder article
• Negative Sentiment: The core allegation is that confidence in Insulet’s manufacturing story “collapsed” after two Omnipod recalls exposed quality failures, which could raise concerns about future product reliability, regulatory scrutiny, and potential financial liabilities. Bleichmar Fonti & Auld lawsuit notice article

Insulet Trading Down 2.2%

Shares of Insulet stock opened at $163.72 on Friday. The firm has a fifty day moving average price of $153.37 and a 200 day moving average price of $204.64. The stock has a market cap of $11.34 billion, a PE ratio of 38.07, a price-to-earnings-growth ratio of 1.17 and a beta of 1.11. Insulet has a 1 year low of $138.79 and a 1 year high of $354.88. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. During the same quarter in the prior year, the business earned $1.02 earnings per share. The company’s revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities research analysts predict that Insulet will post 6.45 earnings per share for the current year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.